Federal Appeals Court Declines to Rehear Zarxio Litigation

A federal appeals court has refused to rehear the biosimilars case pitting Sandoz against Amgen, letting stand a July decision allowing Sandoz to launch its Zarxio biosimilar of Amgen’s cancer therapy Neupogen (filgrastim) in September.

In a two-page order, the U.S. Court of Appeals for the Federal Circuit denied petitions from both companies. Amgen had claimed that the court erred when it found biosimilars makers are not compelled to disclose relevant patent information to the reference product maker.

The July ruling was not a complete win for Sandoz, as the court ruled biosimilar makers must have FDA approval of their product before giving the reference product manufacturer 180-day notice of first commercial marketing of the knock off. Sandoz had argued that the clock should have started ticking when it gave Amgen notice of its intent to market Zarxio in July 2014. Sandoz notified Amgen a second time on March 6 when it received FDA approval, clearing Zarxio for launch after Sept. 2.

Sandoz began marketing Zarxio on Sept. 3, offering a 15 percent discount over Neupogen, after a three-judge panel refused Amgen’s eleventh hour request for a preliminary injunction and a full court review of the July decision (Generic Line, Sept. 16).

The contest may not be over yet. Sandoz told Generic Line it is considering its options, while Amgen said it doesn’t comment on ongoing litigation. — John Bechtel



$1,097 $847


Subscribe to Generic Line and save $250 off the regular one-year price of $1,097 — plus receive a FREE copy of our webinar, Success Strategies for Biosimilars Approval: A Roadmap to the 351(k) Application Process — a $287 Value!

Key Benefits

LINKS TO KEY DOCUMENTS — Each issue provides you with links that support GEN's articles such as FDA guidances, warning letters, rules, full texts of proposed legislation and more.

FDANEWS DRUG DAILY BULLETIN — This daily email brings you important FDA and international regulatory, legislative and business news in the pharmaceutical industry.

ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.